BioDelivery Sciences International (BDSI) has entered into a license and supply agreement with TTY Biopharm, for the exclusive rights to develop and commercialise BEMA Fentanyl (marketed as ONSOLIS in the US) in the Republic of China, Taiwan.

Under the agreement, TTY will be responsible for the regulatory filing of BEMA Fentanyl in Taiwan as well as future commercialisation in that territory.

BEMA Fentanyl is approved in the US and Canada, under the trade name ONSOLIS, for the treatment of breakthrough pain in opioid-tolerant adult patients with cancer.

BDSI president and CEO Mark Sirgo said that they are pleased to have TTY as commercialisation partner for BEMA Fentanyl in Taiwan.